Cargando…

Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions

A poor prognosis of pancreatic ductal adenocarcinoma (PDAC) associated with chemoresistance has not changed for the past three decades. A multidisciplinary diagnosis followed by surgery and chemo(radiation)therapy is the main treatment approach. However, gemcitabine- and 5-fluorouracil-based therapi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yiyin, Yang, Chao, Cheng, He, Fan, Zhiyao, Huang, Qiuyi, Lu, Yu, Fan, Kun, Luo, Guopei, Jin, Kaizhou, Wang, Zhengshi, Liu, Chen, Yu, Xianjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5793409/ https://www.ncbi.nlm.nih.gov/pubmed/29386069 http://dx.doi.org/10.1186/s13045-017-0551-7

Ejemplares similares

Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
por: Qian, Yunzhen, et al.
Publicado: (2020)

Hexokinase 2 dimerization and interaction with voltage‐dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cancer
por: Fan, Kun, et al.
Publicado: (2019)

The CRP/Albumin Ratio Predicts Survival And Monitors Chemotherapeutic Effectiveness In Patients With Advanced Pancreatic Cancer
por: Fan, Zhiyao, et al.
Publicado: (2019)

Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients
por: Cheng, He, et al.
Publicado: (2020)

Prognosis of distal pancreatic cancers controlled by stage
por: Luo, Guopei, et al.
Publicado: (2020)

Absolute Counts of Peripheral Lymphocyte Subsets Correlate with the Progression-Free Survival and Metastatic Status of Pancreatic Neuroendocrine Tumour Patients
por: Gong, Yitao, et al.
Publicado: (2020)

Lewis antigen-negative pancreatic cancer: An aggressive subgroup
por: Liu, Chen, et al.
Publicado: (2020)

Resected Pancreatic Cancer With N2 Node Involvement Is Refractory to Gemcitabine-Based Adjuvant Chemotherapy
por: Liu, Chen, et al.
Publicado: (2020)

The role of necroptosis in cancer biology and therapy
por: Gong, Yitao, et al.
Publicado: (2019)

High GFPT1 expression predicts unfavorable outcomes in patients with resectable pancreatic ductal adenocarcinoma
por: Gong, Yitao, et al.
Publicado: (2021)

Fibrinogen/Albumin Ratio as a Promising Marker for Predicting Survival in Pancreatic Neuroendocrine Neoplasms
por: Deng, Shengming, et al.
Publicado: (2021)

AJCC 7th edition staging classification is more applicable than AJCC 8th edition staging classification for invasive IPMN
por: Fan, Zhiyao, et al.
Publicado: (2019)

Atypical Mucin Expression Predicts Worse Overall Survival in Resectable Pancreatic Ductal Adenocarcinoma
por: Qian, Yunzhen, et al.
Publicado: (2022)

Aberrant APOBEC3C expression induces characteristic genomic instability in pancreatic ductal adenocarcinoma
por: Qian, Yunzhen, et al.
Publicado: (2022)

Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities
por: Jain, Aditi, et al.
Publicado: (2021)

A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma
por: Zhang, Yiyin, et al.
Publicado: (2019)

Somatic Genetic Variation in Solid Pseudopapillary Tumor of the Pancreas by Whole Exome Sequencing
por: Guo, Meng, et al.
Publicado: (2017)

Current and Future Therapies for Pancreatic Ductal Adenocarcinoma
por: Sally, Áine, et al.
Publicado: (2022)

TGF-β1-induced RAP2 regulates invasion in pancreatic cancer: RAP2 regulates invasion in pancreatic cancer
por: Jin, Kaizhou, et al.
Publicado: (2022)

Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma
por: Raufi, Alexander G., et al.
Publicado: (2021)

Nutraceuticals as Supportive Therapeutic Agents in Diabetes and Pancreatic Ductal Adenocarcinoma: A Systematic Review
por: Mikolaskova, Iveta, et al.
Publicado: (2023)

Pancreatic ductal adenocarcinoma: Role of chemotherapy & future perspectives
por: Tiwari, Akash, et al.
Publicado: (2018)

The Role of PDGFRA in Predicting Oncological and Immune Characteristics in Pancreatic Ductal Adenocarcinoma
por: Wu, Zijian, et al.
Publicado: (2022)

Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape
por: Xu, He, et al.
Publicado: (2021)

The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications
por: Liu, Xiaomeng, et al.
Publicado: (2019)

Distribution of Lewis and Secretor polymorphisms and corresponding CA19‐9 antigen expression in a Chinese population
por: Guo, Meng, et al.
Publicado: (2017)

KIF23 enhances cell proliferation in pancreatic ductal adenocarcinoma and is a potent therapeutic target
por: Gao, Chun-Tao, et al.
Publicado: (2020)

Therapeutic Status and Available Strategies in Pancreatic Ductal Adenocarcinoma
por: Thakur, Gitika, et al.
Publicado: (2021)

Hydrogel-Based Therapeutics for Pancreatic Ductal Adenocarcinoma Treatment
por: Liu, Jinlu, et al.
Publicado: (2023)

Possible Molecular Markers for the Diagnosis of Pancreatic Ductal Adenocarcinoma
por: Shen, Quan, et al.
Publicado: (2018)

Research progress and design optimization of CAR‐T therapy for pancreatic ductal adenocarcinoma
por: Li, Tianjiao, et al.
Publicado: (2019)

Subtypes of pancreatic stellate cells and distant metastasis of pancreatic ductal adenocarcinoma
por: Fan, Yuhui, et al.
Publicado: (2020)

Stromal architecture directs early dissemination in pancreatic ductal adenocarcinoma
por: Ray, Arja, et al.
Publicado: (2022)

Clinical implication of serum CA125 for the prediction of malignancy in mucinous cystic neoplasms of the pancreas
por: Deng, Shengming, et al.
Publicado: (2020)

Methylation of CALCA and CALCB in Pancreatic Ductal Adenocarcinoma
por: Gao, Feng, et al.
Publicado: (2021)

Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma
por: Tang, Rong, et al.
Publicado: (2021)

A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics
por: Ocal, Ozhan, et al.
Publicado: (2015)

Pancreatic ductal adenocarcinoma in 2017: Time to change the therapeutic algorithm?
por: Crippa, Stefano, et al.
Publicado: (2017)

The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma
por: Parkin, Ashleigh, et al.
Publicado: (2018)

Targets (Metabolic Mediators) of Therapeutic Importance in Pancreatic Ductal Adenocarcinoma
por: Rai, Vikrant, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_l3csqmui4r7qdsdh7rm5rj9m7t